Interstitial Lung Disease Research Unit Biobank

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
University of Kansas Medical Center
Study ID
NCT05392881
Status
Recruiting
Apply to this trial

Conditions

  • Hypersensitivity Pneumonitis
  • Idiopathic Pulmonary Fibrosis
  • Interstitial Lung Disease
  • Pulmonary Fibrosis
  • Sarcoidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

Key Dates

Start date
Aug 9, 2021
Status verified
Sep 2025
Primary completion
Aug 1, 2031
Completion
Mar 1, 2032

Study Design

Enrollment
1,000 participants (estimated)

Primary Outcome Measure

Collect clinically obtained data for patients with ILD, RLD and risk for ILD/RLD to support research. [ Time Frame: Enrollment to Year 10 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Kansas Medical CenterKansas CityKansas66160
Kimberly Donnelly, Ph.D.
[email protected]
913-588-6067
Chase Hall, M.D. (PRINCIPAL_INVESTIGATOR)
Scott Matson, M.D. (SUB_INVESTIGATOR)
Mark Hamblin, M.D. (SUB_INVESTIGATOR)
Sahil Pandya, M.D (SUB_INVESTIGATOR)
Janell Reichuber, APRN (SUB_INVESTIGATOR)

Find similar trials in Kansas City, KS

By research site
The University of Kansas Medical Center· Kansas City, KS

Related Studies